Apalutamide nanocrystalline formulation (Nanoform Finland Plc)

阿帕他胺纳米晶体制剂 (Nanoform Finland Plc)

Report date: 2025/05/19 16:12:56

Base Information

Drug NameApalutamide nanocrystalline formulation (Nanoform Finland Plc)
Drug Alias Namenanocrystalline-enabled apalutamide oral formulation
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFinland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanoform Finland PLC
China Registration ClassN/A

Develop Information

Active CompaniesNanoform Finland PLC
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A